Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus re-irradiation in recurrent high-grade glioma
ChiCTR2600122533Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in glioma, glioblastoma (GBM) and astrocytoma, sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-Free Survival (PFS). Started Apr 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
gliomaglioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on ChiCTR2600122533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122533.